2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 1/2
3
Phase 1
2
Phase EARLY_PHASE1
1
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
Conditions
Breast Neoplasms
1129
Carcinoma, Non-Small-Cell Lung
718
Neoplasms
546
Prostatic Neoplasms
505
Colorectal Neoplasms
439
Multiple Myeloma
338
Lung Neoplasms
310
Neoplasm Metastasis
289
Leukemia, Myeloid, Acute
263
Stomach Neoplasms
248
Carcinoma, Hepatocellular
246
Ovarian Neoplasms
225
Rectal Neoplasms
211
Colonic Neoplasms
204
Lymphoma, Follicular
200
Lymphoma
199
Leukemia
190
Uterine Cervical Neoplasms
181
Head and Neck Neoplasms
174
Pancreatic Neoplasms
172
Lymphoma, Non-Hodgkin
167
Leukemia, Lymphocytic, Chronic, B-Cell
166
Lymphoma, Large B-Cell, Diffuse
163
Recurrence
162
Melanoma
158
Precursor Cell Lymphoblastic Leukemia-Lymphoma
154
Squamous Cell Carcinoma of Head and Neck
147
Pain
141
Urinary Bladder Neoplasms
139
Brain Neoplasms
133
Interventions
3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Insulin-Like Growth Factor I, Resistance To
×
Clear all
NCT00924989
2024-11-20
GALACCTIC
Astellas Pharma Inc
Phase 3
Completed
139 enrolled